Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis

The COVID-19 pandemic has severely affected adolescents. Safe and effective vaccines are pivotal tools in controlling this pandemic. We reviewed the safety profile of the BNT162b2 COVID-19 vaccine in adolescents using mostly real-world data to assist decision-making. We used random-effects model met...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human vaccines & immunotherapeutics 2022-11, Vol.18 (6), p.2144039-2144039
Hauptverfasser: Katoto, Patrick D. M. C., Brand, Amanda S., Byamungu, Liliane N., Tamuzi, Jacques L., Mahwire, Tamirirashe C., Kitenge, Marcel K., Wiysonge, Charles S., Gray, Glenda
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2144039
container_issue 6
container_start_page 2144039
container_title Human vaccines & immunotherapeutics
container_volume 18
creator Katoto, Patrick D. M. C.
Brand, Amanda S.
Byamungu, Liliane N.
Tamuzi, Jacques L.
Mahwire, Tamirirashe C.
Kitenge, Marcel K.
Wiysonge, Charles S.
Gray, Glenda
description The COVID-19 pandemic has severely affected adolescents. Safe and effective vaccines are pivotal tools in controlling this pandemic. We reviewed the safety profile of the BNT162b2 COVID-19 vaccine in adolescents using mostly real-world data to assist decision-making. We used random-effects model meta-analysis to derive pooled rates of single or grouped adverse events following immunization (AEFI) after each primary and booster dose, as well as after combining all doses. Reporting on over one million participants with safety data were included. The most-reported local and systemic AEFIs were pain/swelling/erythema/redness and fatigue/headache/myalgia, respectively. AESIs were rarely reported but were more frequent after the second dose than they were after the first and the booster doses. Health impact was less common among adolescents after receiving BNT162b2 vaccine. Rare life-threatening AEFIs were reported across all doses in real-world studies. Our findings highlight the significance of enhancing national and regional vaccination programs to ensure public confidence.
doi_str_mv 10.1080/21645515.2022.2144039
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_36367429</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_56d32e80c0e74e4c981ac25f10a11688</doaj_id><sourcerecordid>2735872410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-d8c094554b374ad53700b125b9a86ecd2e140fc50613d351b4b1967be636ff993</originalsourceid><addsrcrecordid>eNp9kk1vEzEQhlcIRKvSnwDysRw2-Nu7HBBp-IpUpQgK4mbNemdTV7vrYm9ShTv_mw1JI3rBF1vjd56Zsd8se87ohNGCvuJMS6WYmnDK-YQzKakoH2XH23iulPzx-HBm6ig7TemGjstQLrV-mh0JLbSRvDzOfn-FBocNCQ2ZXX6fv8tZST43_hfG_NyHxYDumpydL66Y5hV_SboviylZg3O-h8GHnvieQB1aTA77IRFYYk0Yz5khG4SYXpMpSZs0YDfKHYm49nhHoK9JhwPk0EO7ST49y5400CY83e8n2bcP769mn_KLy4_z2fQid0rIIa8LR8txcFkJI6FWwlBaMa6qEgqNrubIJG2copqJWihWyYqV2lQ4jts0ZSlOsvmOWwe4sbfRdxA3NoC3fwMhLi3EsdEWrdK14FhQR9FIlK4sGDiuGkaBMV0UI-vNjnW7qjqst_NHaB9AH970_touw9qWRmpp9Ag42wNi-LnCNNjOj8_YttBjWCXLjVCF4ZLRUap2UhdDShGbQxlG7dYR9t4RdusIu3fEmPfi3x4PWff_Pwre7gS-b0Ls4C7EtrYDbNoQmwi988mK_9f4A7HnwmA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2735872410</pqid></control><display><type>article</type><title>Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Access via Taylor &amp; Francis (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Katoto, Patrick D. M. C. ; Brand, Amanda S. ; Byamungu, Liliane N. ; Tamuzi, Jacques L. ; Mahwire, Tamirirashe C. ; Kitenge, Marcel K. ; Wiysonge, Charles S. ; Gray, Glenda</creator><creatorcontrib>Katoto, Patrick D. M. C. ; Brand, Amanda S. ; Byamungu, Liliane N. ; Tamuzi, Jacques L. ; Mahwire, Tamirirashe C. ; Kitenge, Marcel K. ; Wiysonge, Charles S. ; Gray, Glenda</creatorcontrib><description>The COVID-19 pandemic has severely affected adolescents. Safe and effective vaccines are pivotal tools in controlling this pandemic. We reviewed the safety profile of the BNT162b2 COVID-19 vaccine in adolescents using mostly real-world data to assist decision-making. We used random-effects model meta-analysis to derive pooled rates of single or grouped adverse events following immunization (AEFI) after each primary and booster dose, as well as after combining all doses. Reporting on over one million participants with safety data were included. The most-reported local and systemic AEFIs were pain/swelling/erythema/redness and fatigue/headache/myalgia, respectively. AESIs were rarely reported but were more frequent after the second dose than they were after the first and the booster doses. Health impact was less common among adolescents after receiving BNT162b2 vaccine. Rare life-threatening AEFIs were reported across all doses in real-world studies. Our findings highlight the significance of enhancing national and regional vaccination programs to ensure public confidence.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2022.2144039</identifier><identifier>PMID: 36367429</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Adolescent ; adolescents ; BNT162 Vaccine ; Coronavirus – Review ; COVID-19 ; COVID-19 - prevention &amp; control ; COVID-19 Vaccines - adverse effects ; global surveillance ; Humans ; immunization ; Pandemic ; Pandemics ; Review ; RNA, Messenger ; SARS-CoV-2 ; Vaccination - adverse effects ; youth</subject><ispartof>Human vaccines &amp; immunotherapeutics, 2022-11, Vol.18 (6), p.2144039-2144039</ispartof><rights>2022 The Author(s). Published with license by Taylor &amp; Francis Group, LLC. 2022</rights><rights>2022 The Author(s). Published with license by Taylor &amp; Francis Group, LLC. 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-d8c094554b374ad53700b125b9a86ecd2e140fc50613d351b4b1967be636ff993</citedby><cites>FETCH-LOGICAL-c534t-d8c094554b374ad53700b125b9a86ecd2e140fc50613d351b4b1967be636ff993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746476/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746476/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27502,27924,27925,53791,53793,59143,59144</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36367429$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katoto, Patrick D. M. C.</creatorcontrib><creatorcontrib>Brand, Amanda S.</creatorcontrib><creatorcontrib>Byamungu, Liliane N.</creatorcontrib><creatorcontrib>Tamuzi, Jacques L.</creatorcontrib><creatorcontrib>Mahwire, Tamirirashe C.</creatorcontrib><creatorcontrib>Kitenge, Marcel K.</creatorcontrib><creatorcontrib>Wiysonge, Charles S.</creatorcontrib><creatorcontrib>Gray, Glenda</creatorcontrib><title>Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis</title><title>Human vaccines &amp; immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>The COVID-19 pandemic has severely affected adolescents. Safe and effective vaccines are pivotal tools in controlling this pandemic. We reviewed the safety profile of the BNT162b2 COVID-19 vaccine in adolescents using mostly real-world data to assist decision-making. We used random-effects model meta-analysis to derive pooled rates of single or grouped adverse events following immunization (AEFI) after each primary and booster dose, as well as after combining all doses. Reporting on over one million participants with safety data were included. The most-reported local and systemic AEFIs were pain/swelling/erythema/redness and fatigue/headache/myalgia, respectively. AESIs were rarely reported but were more frequent after the second dose than they were after the first and the booster doses. Health impact was less common among adolescents after receiving BNT162b2 vaccine. Rare life-threatening AEFIs were reported across all doses in real-world studies. Our findings highlight the significance of enhancing national and regional vaccination programs to ensure public confidence.</description><subject>Adolescent</subject><subject>adolescents</subject><subject>BNT162 Vaccine</subject><subject>Coronavirus – Review</subject><subject>COVID-19</subject><subject>COVID-19 - prevention &amp; control</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>global surveillance</subject><subject>Humans</subject><subject>immunization</subject><subject>Pandemic</subject><subject>Pandemics</subject><subject>Review</subject><subject>RNA, Messenger</subject><subject>SARS-CoV-2</subject><subject>Vaccination - adverse effects</subject><subject>youth</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk1vEzEQhlcIRKvSnwDysRw2-Nu7HBBp-IpUpQgK4mbNemdTV7vrYm9ShTv_mw1JI3rBF1vjd56Zsd8se87ohNGCvuJMS6WYmnDK-YQzKakoH2XH23iulPzx-HBm6ig7TemGjstQLrV-mh0JLbSRvDzOfn-FBocNCQ2ZXX6fv8tZST43_hfG_NyHxYDumpydL66Y5hV_SboviylZg3O-h8GHnvieQB1aTA77IRFYYk0Yz5khG4SYXpMpSZs0YDfKHYm49nhHoK9JhwPk0EO7ST49y5400CY83e8n2bcP769mn_KLy4_z2fQid0rIIa8LR8txcFkJI6FWwlBaMa6qEgqNrubIJG2copqJWihWyYqV2lQ4jts0ZSlOsvmOWwe4sbfRdxA3NoC3fwMhLi3EsdEWrdK14FhQR9FIlK4sGDiuGkaBMV0UI-vNjnW7qjqst_NHaB9AH970_touw9qWRmpp9Ag42wNi-LnCNNjOj8_YttBjWCXLjVCF4ZLRUap2UhdDShGbQxlG7dYR9t4RdusIu3fEmPfi3x4PWff_Pwre7gS-b0Ls4C7EtrYDbNoQmwi988mK_9f4A7HnwmA</recordid><startdate>20221130</startdate><enddate>20221130</enddate><creator>Katoto, Patrick D. M. C.</creator><creator>Brand, Amanda S.</creator><creator>Byamungu, Liliane N.</creator><creator>Tamuzi, Jacques L.</creator><creator>Mahwire, Tamirirashe C.</creator><creator>Kitenge, Marcel K.</creator><creator>Wiysonge, Charles S.</creator><creator>Gray, Glenda</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20221130</creationdate><title>Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis</title><author>Katoto, Patrick D. M. C. ; Brand, Amanda S. ; Byamungu, Liliane N. ; Tamuzi, Jacques L. ; Mahwire, Tamirirashe C. ; Kitenge, Marcel K. ; Wiysonge, Charles S. ; Gray, Glenda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-d8c094554b374ad53700b125b9a86ecd2e140fc50613d351b4b1967be636ff993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adolescent</topic><topic>adolescents</topic><topic>BNT162 Vaccine</topic><topic>Coronavirus – Review</topic><topic>COVID-19</topic><topic>COVID-19 - prevention &amp; control</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>global surveillance</topic><topic>Humans</topic><topic>immunization</topic><topic>Pandemic</topic><topic>Pandemics</topic><topic>Review</topic><topic>RNA, Messenger</topic><topic>SARS-CoV-2</topic><topic>Vaccination - adverse effects</topic><topic>youth</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katoto, Patrick D. M. C.</creatorcontrib><creatorcontrib>Brand, Amanda S.</creatorcontrib><creatorcontrib>Byamungu, Liliane N.</creatorcontrib><creatorcontrib>Tamuzi, Jacques L.</creatorcontrib><creatorcontrib>Mahwire, Tamirirashe C.</creatorcontrib><creatorcontrib>Kitenge, Marcel K.</creatorcontrib><creatorcontrib>Wiysonge, Charles S.</creatorcontrib><creatorcontrib>Gray, Glenda</creatorcontrib><collection>Access via Taylor &amp; Francis (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines &amp; immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katoto, Patrick D. M. C.</au><au>Brand, Amanda S.</au><au>Byamungu, Liliane N.</au><au>Tamuzi, Jacques L.</au><au>Mahwire, Tamirirashe C.</au><au>Kitenge, Marcel K.</au><au>Wiysonge, Charles S.</au><au>Gray, Glenda</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis</atitle><jtitle>Human vaccines &amp; immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2022-11-30</date><risdate>2022</risdate><volume>18</volume><issue>6</issue><spage>2144039</spage><epage>2144039</epage><pages>2144039-2144039</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>The COVID-19 pandemic has severely affected adolescents. Safe and effective vaccines are pivotal tools in controlling this pandemic. We reviewed the safety profile of the BNT162b2 COVID-19 vaccine in adolescents using mostly real-world data to assist decision-making. We used random-effects model meta-analysis to derive pooled rates of single or grouped adverse events following immunization (AEFI) after each primary and booster dose, as well as after combining all doses. Reporting on over one million participants with safety data were included. The most-reported local and systemic AEFIs were pain/swelling/erythema/redness and fatigue/headache/myalgia, respectively. AESIs were rarely reported but were more frequent after the second dose than they were after the first and the booster doses. Health impact was less common among adolescents after receiving BNT162b2 vaccine. Rare life-threatening AEFIs were reported across all doses in real-world studies. Our findings highlight the significance of enhancing national and regional vaccination programs to ensure public confidence.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>36367429</pmid><doi>10.1080/21645515.2022.2144039</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2164-5515
ispartof Human vaccines & immunotherapeutics, 2022-11, Vol.18 (6), p.2144039-2144039
issn 2164-5515
2164-554X
language eng
recordid cdi_pubmed_primary_36367429
source MEDLINE; DOAJ Directory of Open Access Journals; Access via Taylor & Francis (Open Access Collection); PubMed Central; Alma/SFX Local Collection
subjects Adolescent
adolescents
BNT162 Vaccine
Coronavirus – Review
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines - adverse effects
global surveillance
Humans
immunization
Pandemic
Pandemics
Review
RNA, Messenger
SARS-CoV-2
Vaccination - adverse effects
youth
title Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A35%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20COVID-19%20Pfizer-BioNtech%20(BNT162b2)%20mRNA%20vaccination%20in%20adolescents%20aged%2012-17%20years:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Katoto,%20Patrick%20D.%20M.%20C.&rft.date=2022-11-30&rft.volume=18&rft.issue=6&rft.spage=2144039&rft.epage=2144039&rft.pages=2144039-2144039&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2022.2144039&rft_dat=%3Cproquest_pubme%3E2735872410%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2735872410&rft_id=info:pmid/36367429&rft_doaj_id=oai_doaj_org_article_56d32e80c0e74e4c981ac25f10a11688&rfr_iscdi=true